Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of TAK-771 in Japanese Patients With Primary Immunodeficiency Disease
NCT05513586Phase 3Completed
- Sponsor
- Takeda
- Start
- Sep 2022
- Primary completion
- Oct 2025
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of immunoglobulin g + hyaluronidase in primary immunodeficiency disease (PID), sponsored by Takeda. Started Sep 2022; status: completed.
02
Drugs
immunoglobulin g + hyaluronidase
03
Conditions
primary immunodeficiency disease (PID)
Beyond the preview
Go deeper on NCT05513586.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05513586.